{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T11:59:31Z","timestamp":1780401571068,"version":"3.54.1"},"reference-count":56,"publisher":"American Society of Hematology","issue":"5","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,3,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Copanlisib is a pan\u2013class I phosphoinositide 3-kinase (PI3K) inhibitor with preferred activity toward PI3K\u03b1 and PI3K\u03b4. Despite the clear overall clinical benefit, the number of patients achieving complete remissions with the single agent is relatively low, a problem shared by the vast majority of targeted agents. Here, we searched for novel copanlisib-based combinations. Copanlisib was tested as a single agent, in combination with an additional 17 drugs in 26 cell lines derived from mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), and T-cell lymphomas. In vivo experiments, transcriptome analyses, and immunoblotting experiments were also performed. Copanlisib as a single agent showed in vitro dose-dependent antitumor activity in the vast majority of the models. Combination screening identified several compounds that synergized with copanlisib. The strongest combination was with the B-cell lymphoma 2 (BCL2) inhibitor venetoclax. The benefit of the combination over single agents was also validated in an MZL xenograft model and in MCL primary cells, and was due to increased induction of apoptosis, an effect likely sustained by the reduction of the antiapoptotic proteins myeloid cell leukemia 1 (MCL1) and BCL-XL, observed in MCL and MZL cell lines, respectively. These data supported the rationale for the design of the Swiss Group for Clinical Cancer Research (SAKK) 66\/18 phase 1 study currently exploring the combination of copanlisib and venetoclax in relapsed\/refractory lymphomas.<\/jats:p>","DOI":"10.1182\/bloodadvances.2019000844","type":"journal-article","created":{"date-parts":[[2020,3,3]],"date-time":"2020-03-03T18:35:27Z","timestamp":1583260527000},"page":"819-829","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":33,"title":["Copanlisib synergizes with conventional and targeted agents including venetoclax in B- and T-cell lymphoma models"],"prefix":"10.1182","volume":"4","author":[{"given":"Chiara","family":"Tarantelli","sequence":"first","affiliation":[{"name":"Institute of Oncology Research, Faculty of Biomedical Sciences, Universit\u00e0 della Svizzera Italiana (USI), Bellinzona, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Lange","sequence":"first","affiliation":[{"name":"Bayer AG, Berlin, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenio","family":"Gaudio","sequence":"first","affiliation":[{"name":"Institute of Oncology Research, Faculty of Biomedical Sciences, Universit\u00e0 della Svizzera Italiana (USI), Bellinzona, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4606-0637","authenticated-orcid":false,"given":"Luciano","family":"Cascione","sequence":"first","affiliation":[{"name":"Institute of Oncology Research, Faculty of Biomedical Sciences, Universit\u00e0 della Svizzera Italiana (USI), Bellinzona, Switzerland;"},{"name":"Swiss Institute of Bioinformatics, Lausanne, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Spriano","sequence":"first","affiliation":[{"name":"Institute of Oncology Research, Faculty of Biomedical Sciences, Universit\u00e0 della Svizzera Italiana (USI), Bellinzona, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivo","family":"Kwee","sequence":"first","affiliation":[{"name":"Institute of Oncology Research, Faculty of Biomedical Sciences, Universit\u00e0 della Svizzera Italiana (USI), Bellinzona, Switzerland;"},{"name":"Swiss Institute of Bioinformatics, Lausanne, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto J.","family":"Arribas","sequence":"first","affiliation":[{"name":"Institute of Oncology Research, Faculty of Biomedical Sciences, Universit\u00e0 della Svizzera Italiana (USI), Bellinzona, Switzerland;"},{"name":"Swiss Institute of Bioinformatics, Lausanne, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3234-0563","authenticated-orcid":false,"given":"Andrea","family":"Rinaldi","sequence":"first","affiliation":[{"name":"Institute of Oncology Research, Faculty of Biomedical Sciences, Universit\u00e0 della Svizzera Italiana (USI), Bellinzona, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thibaud","family":"Jourdan","sequence":"first","affiliation":[{"name":"Bayer AG, Berlin, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Berthold","sequence":"first","affiliation":[{"name":"Bayer AG, Berlin, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Sturz","sequence":"first","affiliation":[{"name":"Bayer AG, Berlin, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn","family":"Sperl","sequence":"first","affiliation":[{"name":"Bayer AG, Berlin, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Margheriti","sequence":"first","affiliation":[{"name":"Institute of Oncology Research, Faculty of Biomedical Sciences, Universit\u00e0 della Svizzera Italiana (USI), Bellinzona, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Scalise","sequence":"first","affiliation":[{"name":"Institute of Oncology Research, Faculty of Biomedical Sciences, Universit\u00e0 della Svizzera Italiana (USI), Bellinzona, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Gritti","sequence":"first","affiliation":[{"name":"Unit\u00e0 Strutturale Complessa Ematologia, Ospedale Papa Giovanni XXIII, Bergamo, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Rossi","sequence":"first","affiliation":[{"name":"Institute of Oncology Research, Faculty of Biomedical Sciences, Universit\u00e0 della Svizzera Italiana (USI), Bellinzona, Switzerland;"},{"name":"Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasios","family":"Stathis","sequence":"first","affiliation":[{"name":"Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; and"},{"name":"Faculty of Biomedical Sciences, USI, Lugano, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ningshu","family":"Liu","sequence":"first","affiliation":[{"name":"Bayer AG, Berlin, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5522-6109","authenticated-orcid":false,"given":"Emanuele","family":"Zucca","sequence":"first","affiliation":[{"name":"Institute of Oncology Research, Faculty of Biomedical Sciences, Universit\u00e0 della Svizzera Italiana (USI), Bellinzona, Switzerland;"},{"name":"Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0272-6249","authenticated-orcid":false,"given":"Oliver","family":"Politz","sequence":"first","affiliation":[{"name":"Bayer AG, Berlin, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5637-8983","authenticated-orcid":false,"given":"Francesco","family":"Bertoni","sequence":"first","affiliation":[{"name":"Institute of Oncology Research, Faculty of Biomedical Sciences, Universit\u00e0 della Svizzera Italiana (USI), Bellinzona, Switzerland;"},{"name":"Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2020,3,3]]},"reference":[{"issue":"1","key":"2020030912202181300_B1","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/bjh.13065","article-title":"Targeting PI3-kinase (PI3K), AKT and mTOR axis in lymphoma","volume":"167","author":"Blachly","year":"2014","journal-title":"Br J Haematol"},{"issue":"3","key":"2020030912202181300_B2","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/nrc.2017.121","article-title":"Targeting B cell receptor signalling in cancer: preclinical and clinical advances","volume":"18","author":"Burger","year":"2018","journal-title":"Nat Rev Cancer"},{"issue":"7","key":"2020030912202181300_B3","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1158\/1078-0432.CCR-14-2522","article-title":"FDA approval: idelalisib monotherapy for the treatment of patients with follicular lymphoma and small lymphocytic lymphoma","volume":"21","author":"Miller","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"11","key":"2020030912202181300_B4","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1056\/NEJMoa1314583","article-title":"PI3K\u03b4 inhibition by idelalisib in patients with relapsed indolent lymphoma","volume":"370","author":"Gopal","year":"2014","journal-title":"N Engl J Med"},{"issue":"22","key":"2020030912202181300_B5","doi-asserted-by":"crossref","first-page":"3398","DOI":"10.1182\/blood-2013-11-537555","article-title":"A phase 1 study of the PI3K\u03b4 inhibitor idelalisib in patients with relapsed\/refractory mantle cell lymphoma (MCL)","volume":"123","author":"Kahl","year":"2014","journal-title":"Blood"},{"issue":"12","key":"2020030912202181300_B6","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1182\/blood-2012-10-460832","article-title":"P110\u03b1-mediated constitutive PI3K signaling limits the efficacy of p110\u03b4-selective inhibition in mantle cell lymphoma, particularly with multiple relapse","volume":"121","author":"Iyengar","year":"2013","journal-title":"Blood"},{"issue":"1","key":"2020030912202181300_B7","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.ccell.2016.12.003","article-title":"Simultaneous inhibition of PI3K\u03b4 and PI3K\u03b1 induces ABC-DLBCL regression by blocking BCR-dependent and -independent activation of NF-\u03baB and AKT","volume":"31","author":"Paul","year":"2017","journal-title":"Cancer Cell"},{"issue":"1","key":"2020030912202181300_B8","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1158\/1078-0432.CCR-17-1041","article-title":"PQR309 is a novel dual PI3K\/mTOR inhibitor with preclinical antitumor activity in lymphomas as a single agent and in combination therapy","volume":"24","author":"Tarantelli","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2020030912202181300_B9","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1159\/000353164","article-title":"Class IA PI3K inhibition inhibits cell growth and proliferation in mantle cell lymphoma","volume":"131","author":"Tabe","year":"2014","journal-title":"Acta Haematol"},{"issue":"1","key":"2020030912202181300_B10","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1182\/blood-2018-08-872465","article-title":"Targeted inhibition of PI3K\u03b1\/\u03b4 is synergistic with BCL-2 blockade in genetically defined subtypes of DLBCL","volume":"133","author":"Bojarczuk","year":"2019","journal-title":"Blood"},{"issue":"9","key":"2020030912202181300_B11","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1002\/ijc.29579","article-title":"Efficacy of phosphatidylinositol-3 kinase inhibitors with diverse isoform selectivity profiles for inhibiting the survival of chronic lymphocytic leukemia cells","volume":"137","author":"Gockeritz","year":"2015","journal-title":"Int J Cancer"},{"issue":"1","key":"2020030912202181300_B12","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3324\/haematol.2012.068510","article-title":"Simultaneous inhibition of pan-phosphatidylinositol-3-kinases and MEK as a potential therapeutic strategy in peripheral T-cell lymphomas","volume":"98","author":"Mart\u00edn-S\u00e1nchez","year":"2013","journal-title":"Haematologica"},{"issue":"8","key":"2020030912202181300_B13","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1182\/blood-2017-08-802470","article-title":"Activity of the PI3K-\u03b4,\u03b3 inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma","volume":"131","author":"Horwitz","year":"2018","journal-title":"Blood"},{"issue":"14","key":"2020030912202181300_B14","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1002\/cmdc.201600148","article-title":"Discovery and SAR of novel 2,3-dihydroimidazo[1,2-c]quinazoline PI3K inhibitors: identification of copanlisib (BAY 80-6946)","volume":"11","author":"Scott","year":"2016","journal-title":"ChemMedChem"},{"issue":"11","key":"2020030912202181300_B15","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1158\/1535-7163.MCT-12-0993-T","article-title":"BAY 80-6946 is a highly selective intravenous PI3K inhibitor with potent p110\u03b1 and p110\u03b4 activities in tumor cell lines and xenograft models","volume":"12","author":"Liu","year":"2013","journal-title":"Mol Cancer Ther"},{"issue":"10","key":"2020030912202181300_B16","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1093\/annonc\/mdw282","article-title":"First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin\u2019s lymphomas","volume":"27","author":"Patnaik","year":"2016","journal-title":"Ann Oncol"},{"issue":"9","key":"2020030912202181300_B17","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1093\/annonc\/mdx289","article-title":"Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma","volume":"28","author":"Dreyling","year":"2017","journal-title":"Ann Oncol"},{"issue":"35","key":"2020030912202181300_B18","doi-asserted-by":"crossref","first-page":"3898","DOI":"10.1200\/JCO.2017.75.4648","article-title":"Phosphatidylinositol 3-kinase inhibition by copanlisib in relapsed or refractory indolent lymphoma","volume":"35","author":"Dreyling","year":"2017","journal-title":"J Clin Oncol"},{"key":"2020030912202181300_B19","article-title":"Long-term safety and efficacy of the PI3K inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2-year follow-up of the CHRONOS-1 study [published online ahead of print 23 December 2019]","author":"Dreyling","journal-title":"Am J Hematol"},{"key":"2020030912202181300_B20","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.2147\/DDDT.S142406","article-title":"Copanlisib for treatment of B-cell malignancies: the development of a PI3K inhibitor with considerable differences to idelalisib","volume":"12","author":"Krause","year":"2018","journal-title":"Drug Des Devel Ther"},{"issue":"9","key":"2020030912202181300_B21","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1177\/1060028019833992","article-title":"Copanlisib: an intravenous phosphatidylinositol 3-kinase (PI3K) inhibitor for the treatment of relapsed follicular lymphoma","volume":"53","author":"Eltantawy","year":"2019","journal-title":"Ann Pharmacother"},{"issue":"suppl 1","key":"2020030912202181300_B22","doi-asserted-by":"crossref","first-page":"Abstract 4009","DOI":"10.1182\/blood-2019-131779","article-title":"Copanlisib, a PI3K inhibitor, demonstrates a favorable long-term safety profile in a pooled analysis of patients with hematologic malignancies [abstract]","volume":"134","author":"Zinzani","year":"2019","journal-title":"Blood"},{"issue":"6","key":"2020030912202181300_B23","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1056\/NEJMe1307596","article-title":"Toward new treatments for mantle-cell lymphoma?","volume":"369","author":"Zucca","year":"2013","journal-title":"N Engl J Med"},{"issue":"5","key":"2020030912202181300_B24","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/nrclinonc.2018.28","article-title":"Targeting the PI3K pathway in cancer: are we making headway?","volume":"15","author":"Janku","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"2020030912202181300_B25","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0065-2571(84)90007-4","article-title":"Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors","volume":"22","author":"Chou","year":"1984","journal-title":"Adv Enzyme Regul"},{"issue":"16","key":"2020030912202181300_B26","doi-asserted-by":"crossref","first-page":"5167","DOI":"10.1158\/1078-0432.CCR-18-2718","article-title":"The ETS inhibitors YK-4-279 and TK-216 are novel anti-lymphoma agents","volume":"25","author":"Spriano","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"12","key":"2020030912202181300_B27","doi-asserted-by":"crossref","first-page":"e558","DOI":"10.3324\/haematol.2018.214957","article-title":"Novel insights into the genetics and epigenetics of MALT lymphoma unveiled by next generation sequencing analyses","volume":"104","author":"Cascione","year":"2019","journal-title":"Haematologica"},{"issue":"43","key":"2020030912202181300_B28","doi-asserted-by":"crossref","first-page":"15545","DOI":"10.1073\/pnas.0506580102","article-title":"Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles","volume":"102","author":"Subramanian","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"issue":"15","key":"2020030912202181300_B29","doi-asserted-by":"crossref","first-page":"2683","DOI":"10.1182\/blood-2013-04-497933","article-title":"PRDM1\/BLIMP1 is commonly inactivated in anaplastic large T-cell lymphoma","volume":"122","author":"Boi","year":"2013","journal-title":"Blood"},{"issue":"19","key":"2020030912202181300_B30","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1182\/blood-2018-07-859769","article-title":"Five-year follow-up of lenalidomide plus rituximab as initial treatment of mantle cell lymphoma","volume":"132","author":"Ruan","year":"2018","journal-title":"Blood"},{"issue":"3","key":"2020030912202181300_B31","doi-asserted-by":"crossref","first-page":"353","DOI":"10.3324\/haematol.2012.065995","article-title":"A phase II study of lenalidomide in patients with extranodal marginal zone B-cell lymphoma of the mucosa associated lymphoid tissue (MALT lymphoma)","volume":"98","author":"Kiesewetter","year":"2013","journal-title":"Haematologica"},{"issue":"13","key":"2020030912202181300_B32","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1158\/1078-0432.CCR-17-2369","article-title":"FDA approval: ribociclib for the treatment of postmenopausal women with hormone receptor-positive, HER2-negative advanced or metastatic breast cancer","volume":"24","author":"Shah","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"20","key":"2020030912202181300_B33","doi-asserted-by":"crossref","first-page":"4968","DOI":"10.1158\/1078-0432.CCR-16-0493","article-title":"FDA approval of palbociclib in combination with fulvestrant for the treatment of hormone receptor-positive, HER2-negative metastatic breast cancer","volume":"22","author":"Walker","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"5","key":"2020030912202181300_B34","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1182\/blood-2006-04-016634","article-title":"Mantle cell lymphoma cells express predominantly cyclin D1a isoform and are highly sensitive to selective inhibition of CDK4 kinase activity","volume":"108","author":"Marzec","year":"2006","journal-title":"Blood"},{"issue":"20","key":"2020030912202181300_B35","doi-asserted-by":"crossref","first-page":"4597","DOI":"10.1182\/blood-2011-10-388298","article-title":"Selective CDK4\/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma","volume":"119","author":"Leonard","year":"2012","journal-title":"Blood"},{"issue":"9","key":"2020030912202181300_B36","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1158\/2159-8290.CD-14-0098","article-title":"Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma [published correction appears in Cancer Discov. 2019;9(11):1629]","volume":"4","author":"Chiron","year":"2014","journal-title":"Cancer Discov"},{"issue":"12","key":"2020030912202181300_B37","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.4161\/cc.24928","article-title":"Induction of prolonged early G1 arrest by CDK4\/CDK6 inhibition reprograms lymphoma cells for durable PI3K\u03b4 inhibition through PIK3IP1","volume":"12","author":"Chiron","year":"2013","journal-title":"Cell Cycle"},{"issue":"13","key":"2020030912202181300_B38","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1182\/blood-2015-04-639542","article-title":"Synergistic activity of BET protein antagonist-based combinations in mantle cell lymphoma cells sensitive or resistant to ibrutinib [published correction appears in Blood. 2016;128(13):1778]","volume":"126","author":"Sun","year":"2015","journal-title":"Blood"},{"issue":"43","key":"2020030912202181300_B39","doi-asserted-by":"crossref","first-page":"70000","DOI":"10.18632\/oncotarget.12132","article-title":"Acquired resistance to venetoclax (ABT-199) in t(14;18) positive lymphoma cells","volume":"7","author":"Bodo","year":"2016","journal-title":"Oncotarget"},{"issue":"16","key":"2020030912202181300_B40","doi-asserted-by":"crossref","first-page":"3967","DOI":"10.1158\/1078-0432.CCR-17-3004","article-title":"Strategic therapeutic targeting to overcome venetoclax resistance in aggressive B-cell lymphomas","volume":"24","author":"Pham","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"6","key":"2020030912202181300_B41","doi-asserted-by":"crossref","first-page":"775","DOI":"10.3390\/cancers11060775","article-title":"The novel TORC1\/2 kinase inhibitor PQR620 has anti-tumor activity in lymphomas as a single agent and in combination with venetoclax","volume":"11","author":"Tarantelli","year":"2019","journal-title":"Cancers (Basel)"},{"key":"2020030912202181300_B42","doi-asserted-by":"crossref","first-page":"212574","DOI":"10.7573\/dic.212574","article-title":"Venetoclax: evidence to date and clinical potential","volume":"8","author":"Ju\u00e1rez-Salcedo","year":"2019","journal-title":"Drugs Context"},{"issue":"18","key":"2020030912202181300_B43","doi-asserted-by":"crossref","first-page":"4371","DOI":"10.1158\/1078-0432.CCR-17-3761","article-title":"Comprehensive safety analysis of venetoclax monotherapy for patients with relapsed\/refractory chronic lymphocytic leukemia","volume":"24","author":"Davids","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"8","key":"2020030912202181300_B44","doi-asserted-by":"crossref","first-page":"e0200725","DOI":"10.1371\/journal.pone.0200725","article-title":"The phosphoinositide-3 kinase (PI3K)-\u03b4,\u03b3 inhibitor, duvelisib shows preclinical synergy with multiple targeted therapies in hematologic malignancies","volume":"13","author":"Faia","year":"2018","journal-title":"PLoS One"},{"issue":"34","key":"2020030912202181300_B45","doi-asserted-by":"crossref","first-page":"35202","DOI":"10.18632\/oncotarget.6051","article-title":"MCL-1-independent mechanisms of synergy between dual PI3K\/mTOR and BCL-2 inhibition in diffuse large B cell lymphoma","volume":"6","author":"Lee","year":"2015","journal-title":"Oncotarget"},{"issue":"19","key":"2020030912202181300_B46","doi-asserted-by":"crossref","first-page":"5814","DOI":"10.1158\/1078-0432.CCR-17-0650","article-title":"Combined BTK and PI3K\u03b4 inhibition with acalabrutinib and ACP-319 improves survival and tumor control in CLL mouse model","volume":"23","author":"Niemann","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"6","key":"2020030912202181300_B47","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1073\/pnas.1311846111","article-title":"High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell-like diffuse large B-cell lymphoma cells","volume":"111","author":"Mathews Griner","year":"2014","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"2020030912202181300_B48","doi-asserted-by":"crossref","first-page":"e0171221","DOI":"10.1371\/journal.pone.0171221","article-title":"PI3K\u03b4 inhibitor idelalisib in combination with BTK inhibitor ONO\/GS-4059 in diffuse large B cell lymphoma with acquired resistance to PI3K\u03b4 and BTK inhibitors","volume":"12","author":"Yahiaoui","year":"2017","journal-title":"PLoS One"},{"issue":"5","key":"2020030912202181300_B49","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1111\/bjh.16118","article-title":"Single and combined BTK and PI3K\u03b4 inhibition with acalabrutinib and ACP-319 in pre- clinical models of aggressive lymphomas","volume":"187","author":"Spriano","year":"2019","journal-title":"Br J Haematol"},{"issue":"4","key":"2020030912202181300_B50","doi-asserted-by":"crossref","first-page":"e176","DOI":"10.1016\/S2352-3026(17)30028-5","article-title":"Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials","volume":"4","author":"Smith","year":"2017","journal-title":"Lancet Haematol"},{"issue":"6","key":"2020030912202181300_B51","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1080\/10428194.2016.1247956","article-title":"Targeting histone deacetylases in T-cell lymphoma","volume":"58","author":"Moskowitz","year":"2017","journal-title":"Leuk Lymphoma"},{"issue":"18","key":"2020030912202181300_B52","doi-asserted-by":"crossref","first-page":"4849","DOI":"10.1158\/1078-0432.CCR-14-0034","article-title":"PI3K\/mTOR inhibition markedly potentiates HDAC inhibitor activity in NHL cells through BIM- and MCL-1-dependent mechanisms in vitro and in vivo","volume":"20","author":"Rahmani","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"10","key":"2020030912202181300_B53","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1158\/1535-7163.MCT-12-0286","article-title":"BAY 1000394, a novel cyclin-dependent kinase inhibitor, with potent antitumor activity in mono- and in combination treatment upon oral application","volume":"11","author":"Siemeister","year":"2012","journal-title":"Mol Cancer Ther"},{"issue":"12","key":"2020030912202181300_B54","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1038\/bjc.2017.92","article-title":"Phase I dose-escalation studies of roniciclib, a pan-cyclin-dependent kinase inhibitor, in advanced malignancies","volume":"116","author":"Bahleda","year":"2017","journal-title":"Br J Cancer"},{"issue":"9","key":"2020030912202181300_B55","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1182\/blood-2016-09-741983","article-title":"Cyclin-dependent kinase 9 is a novel specific molecular target in adult T-cell leukemia\/lymphoma","volume":"130","author":"Narita","year":"2017","journal-title":"Blood"},{"issue":"21","key":"2020030912202181300_B56","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1002\/cmdc.201700447","article-title":"Identification of atuveciclib (BAY 1143572), the first highly selective, clinical PTEFb\/CDK9 inhibitor for the treatment of cancer","volume":"12","author":"L\u00fccking","year":"2017","journal-title":"ChemMedChem"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/4\/5\/819\/1718050\/advancesadv2019000844.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/4\/5\/819\/1718050\/advancesadv2019000844.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,9]],"date-time":"2020-03-09T16:20:53Z","timestamp":1583770853000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/4\/5\/819\/452604\/Copanlisib-synergizes-with-conventional-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,3]]},"references-count":56,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,3,10]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2019000844","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,3]]}}}